Fig. 5From: Selpercatinib for treating recurrent mixed medullary and follicular cell-derived thyroid carcinoma: a case reportComputed tomography (CT) scans before and after selpercatinib treatment. CT scans at 11 months postoperatively revealed recurrence of mixed medullary and follicular cell-derived thyroid carcinoma at the right cervical lymph nodes (a) and upper mediastinal lymph nodes (b). After 9 weeks of treatment with selpercatinib, the cervical (c) and mediastinal lymph nodes (d) showed a reduction in sizeBack to article page